Skip to main content
SpringerLink
Log in

Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade

  • Chapter
  • First Online:
Substance Use Disorders

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 258))

Abstract

Every year, billions of dollars are spent treating smoking and related conditions, yet smoking-related morbidity and mortality continue to rise. There are currently only three FDA-approved medications for smoking cessation: nicotine replacement therapy, bupropion, and varenicline. Although these medications increase abstinence rates, most individuals relapse following treatment. This chapter reviews clinical trials published within the past 10 years investigating novel smoking cessation pharmacotherapies. Among these pharmacotherapies, some showed promising results, such as cytisine and endocannabinoid modulators, whereas others failed to produce significant effects. More research is needed to develop drugs that produce higher rates of long-term abstinence and to determine which subgroups of patients benefit from a given treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alhadeff AL, Rupprecht LE, Hayes MR (2012) GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153:647–658

    Article  CAS  PubMed  Google Scholar 

  • Allen SS, Allen AM, Lunos S, Tosun N (2016) Progesterone and postpartum smoking relapse: a pilot double-blind placebo-controlled randomized trial. Nicotine Tob Res 18:2145–2153

    Article  PubMed  PubMed Central  Google Scholar 

  • Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL (1990) Depression and the dynamics of smoking. A national perspective. JAMA 264:1541–1545

    Article  CAS  PubMed  Google Scholar 

  • Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr (2008) Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 103:687–694

    Article  PubMed  Google Scholar 

  • Anthenelli RM, Heffner JL, Wong E, Tibbs J, Russell K, Isgro M, Dinh E, Wehrle C, Worley MJ, Doran N (2017) A randomized trial evaluating whether topiramate aids smoking cessation and prevents alcohol relapse in recovering alcohol-dependent men. Alcohol Clin Exp Res 41:197–206

    Article  CAS  PubMed  Google Scholar 

  • Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M (2008) Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 336:1223–1227

    Article  PubMed  PubMed Central  Google Scholar 

  • Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 22:9134–9141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ballon JS, Feifel D (2006) A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 67:554–566

    Article  CAS  PubMed  Google Scholar 

  • Baltieri DA, Daro FR, Ribeiro PL, Andrade AG (2009) Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend 105:33–41

    Article  CAS  PubMed  Google Scholar 

  • Benowitz NL (2010) Nicotine addiction. N Engl J Med 362:2295–2303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Benowitz NL, Wilson Peng M (2000) Non-nicotine pharmacotherapy for smoking cessation: mechanisms and prospects. CNS Drugs 13:265–285

    Article  CAS  Google Scholar 

  • Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237–249

    Article  CAS  PubMed  Google Scholar 

  • Berlin I, Hunneyball IM, Greiling D, Jones SP, Fuder H, Stahl HD (2012) A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Psychopharmacology 223:89–98

    Article  CAS  PubMed  Google Scholar 

  • Biberman R, Neumann R, Katzir I, Gerber Y (2003) A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 98:1403–1407

    Article  CAS  PubMed  Google Scholar 

  • Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F, Nilsson F, Bjornsdottir US (1999) The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial. Addiction 94:1007–1015

    Article  CAS  PubMed  Google Scholar 

  • Bozinoff N, Le Foll B (2018) Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. Expert Rev Respir Med 12:793–804

    Article  CAS  PubMed  Google Scholar 

  • Brown RA, Abrantes AM, Strong DR, Niaura R, Kahler CW, Miller IW, Price LH (2014) Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. Nicotine Tob Res 16:197–207

    Article  CAS  PubMed  Google Scholar 

  • Burki TK (2015) WHO tobacco report focuses on increased taxation. Lancet Respir Med 3:604

    Article  PubMed  Google Scholar 

  • Butterweck V (2003) Mechanism of action of St John’s wort in depression: what is known? CNS Drugs 17:539–562

    Article  CAS  PubMed  Google Scholar 

  • Cahill K, Stead LF, Lancaster T (2007) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 4:CD006103

    Google Scholar 

  • Cahill K, Stevens S, Perera R, Lancaster T (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 5:CD009329

    Google Scholar 

  • Catania MA, Firenzuoli F, Crupi A, Mannucci C, Caputi AP, Calapai G (2003) Hypericum perforatum attenuates nicotine withdrawal signs in mice. Psychopharmacology 169:186–189

    Article  CAS  PubMed  Google Scholar 

  • Chauvet C, Nicolas C, Lafay-Chebassier C, Jaber M, Thiriet N, Solinas M (2016) Statins reduce the risks of relapse to addiction in rats. Neuropsychopharmacology 41:1588–1597

    Article  CAS  PubMed  Google Scholar 

  • Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD, O’Neill BT (2005) Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477

    Article  CAS  PubMed  Google Scholar 

  • Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451–463

    Article  CAS  PubMed  Google Scholar 

  • Curioni C, Andre C (2006) Rimonabant for overweight or obesity. Cochrane Database Syst Rev 4:Cd006162

    Google Scholar 

  • Dalack GW, Glassman AH, Rivelli S, Covey L, Stetner F (1995) Mood, major depression, and fluoxetine response in cigarette smokers. Am J Psychiatry 152:398–403

    Article  CAS  PubMed  Google Scholar 

  • David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ (2013) Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 6:CD003086

    Google Scholar 

  • David SP, Chu IM, Lancaster T, Stead LF, Evins AE, Prochaska JJ (2014) Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ Open 4:e004393

    Article  PubMed  PubMed Central  Google Scholar 

  • De la Garza R 2nd, Yoon JH (2011) Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. Prog Neuro-Psychopharmacol Biol Psychiatry 35:1827–1830

    Article  CAS  Google Scholar 

  • Diehl A, Nakovics H, Mutschler J, Hermann D, Kiefer F (2009) Rivastigmine reduces tobacco craving in alcohol-dependent smokers. Pharmacopsychiatry 42:89–94

    Article  CAS  PubMed  Google Scholar 

  • Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA (1995) Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr 61:1206–1212

    Article  CAS  PubMed  Google Scholar 

  • Dunn KE, Marcus TF, Kim C, Schroeder JR, Vandrey R, Umbricht A (2016) Zonisamide reduces withdrawal symptoms but does not enhance varenicline-induced smoking cessation. Nicotine Tob Res 18:1171–1179

    Article  PubMed  Google Scholar 

  • Egecioglu E, Engel JA, Jerlhag E (2013a) The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One 8:e77284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Egecioglu E, Engel JA, Jerlhag E (2013b) The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One 8:e69010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E (2013c) The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38:1259–1270

    Article  CAS  PubMed  Google Scholar 

  • Elrashidi MY, Ebbert JO (2014) Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs 19:243–260

    Article  CAS  PubMed  Google Scholar 

  • Epstein AM, King AC (2004) Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav 77:29–37

    Article  CAS  PubMed  Google Scholar 

  • Erreger K, Davis AR, Poe AM, Greig NH, Stanwood GD, Galli A (2012) Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav 106:574–578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M (2011) A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol 31:597–602

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19:353–364

    Article  PubMed  Google Scholar 

  • Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763

    Article  PubMed  Google Scholar 

  • Feighner JP (1999) Mechanism of action of antidepressant medications. J Clin Psychiatry 60(Suppl 4):4–11; discussion 12-3

    CAS  PubMed  Google Scholar 

  • Fiedorowicz JG, Swartz KL (2004) The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 10:239–248

    Article  PubMed  PubMed Central  Google Scholar 

  • Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A (2004) Smoking cessation and weight gain. Obes Rev 5:95–103

    Article  CAS  PubMed  Google Scholar 

  • Forget B, Wertheim C, Mascia P, Pushparaj A, Goldberg SR, Le Foll B (2010) Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology 35:1751–1760

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R et al (2015) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:2287–2323

    Article  PubMed  Google Scholar 

  • Forray A, Gilstad-Hayden K, Suppies C, Bogen D, Sofuoglu M, Yonkers KA (2017) Progesterone for smoking relapse prevention following delivery: a pilot, randomized, double-blind study. Psychoneuroendocrinology 86:96–103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Franklin TR, Harper D, Kampman K, Kildea-McCrea S, Jens W, Lynch KG, O’Brien CP, Childress AR (2009) The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 103:30–36

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garnock-Jones KP, Keating GM (2009) Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11:203–226

    Article  PubMed  Google Scholar 

  • Gehricke JG, Hong N, Wigal TL, Chan V, Doan A (2011) ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav 98:485–491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O’Malley SS (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 53:136–143

    Article  CAS  PubMed  Google Scholar 

  • Glover ED, Laflin MT, Schuh KJ, Schuh LM, Nides M, Christen AG, Glover PN, Strnad JV (2007) A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 102:795–802

    Article  PubMed  Google Scholar 

  • Goodchild M, Nargis N, Tursan d’Espaignet E (2018) Global economic cost of smoking-attributable diseases. Tob Control 27:58–64

    Article  PubMed  Google Scholar 

  • Gourlay SG, Stead LF, Benowitz NL (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev 3:CD000058

    Google Scholar 

  • Government of Canada (2018) Licensed natural health products database (LNHPD): product information. Retrieved from https://health-products.canada.ca/lnhpd-bdpsnh/info.do?licence=80072429

  • Gowing LR, Ali RL, Allsop S, Marsden J, Turf EE, West R, Witton J (2015) Global statistics on addictive behaviours: 2014 status report. Addiction 110:904–919

    Article  PubMed  Google Scholar 

  • Graham DL, Erreger K, Galli A, Stanwood GD (2013) GLP-1 analog attenuates cocaine reward. Mol Psychiatry 18:961–962

    Article  CAS  PubMed  Google Scholar 

  • Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316–1322

    Article  CAS  PubMed  Google Scholar 

  • Herman AI, Waters AJ, McKee SA, Sofuoglu M (2012) Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers. Psychopharmacology 220:611–617

    Article  CAS  PubMed  Google Scholar 

  • Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ (2012) The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology 37:1177–1191

    Article  CAS  PubMed  Google Scholar 

  • Holst JJ, Seino Y (2009) GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes. Diabetes Res Clin Pract 85:1–3

    Article  CAS  PubMed  Google Scholar 

  • Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T (2014) Antidepressants for smoking cessation. Cochrane Database Syst Rev 1:CD000031

    Google Scholar 

  • Hurt RT, Croghan IT, Schroeder DR, Hays JT, Choi DS, Ebbert JO (2017) Combination varenicline and lorcaserin for tobacco dependence treatment and weight gain prevention in overweight and obese smokers: a pilot study. Nicotine Tob Res 19:994–998

    CAS  PubMed  Google Scholar 

  • Hutchison KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Gnys M, Niaura RS, Sirota AD (1999) Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology 142:139–143

    Article  CAS  PubMed  Google Scholar 

  • Ingrand I, Solinas M, Ingrand P, Dugast E, Saulnier PJ, Perault-Pochat MC, Lafay-Chebassier C (2018) Lack of effects of simvastatin on smoking cessation in humans: a double-blind, randomized, placebo-controlled clinical study. Sci Rep 8:3836

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Izaddoost M, Harris BG, Gracy RW (1976) Structure and toxicity of alkaloids and amino acids of Sophora secundiflora. J Pharm Sci 65:352–354

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA (2004) Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 29:1465–1479

    Article  PubMed  Google Scholar 

  • Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, Jackson T, Williams J, Murtaugh C, Montoya I, Yu E, Elkashef A (2012) Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res 14:377–382

    Article  CAS  PubMed  Google Scholar 

  • Kalivas PW, LaLumiere RT, Knackstedt L, Shen H (2009) Glutamate transmission in addiction. Neuropharmacology 56:169–173

    Article  CAS  PubMed  Google Scholar 

  • Kamboj SK, Joye A, Das RK, Gibson AJ, Morgan CJ, Curran HV (2012) Cue exposure and response prevention with heavy smokers: a laboratory-based randomised placebo-controlled trial examining the effects of D-cycloserine on cue reactivity and attentional bias. Psychopharmacology 221:273–284

    Article  CAS  PubMed  Google Scholar 

  • Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, Leggio L (2016) Role of the alpha1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol 21:904–914

    Article  CAS  PubMed  Google Scholar 

  • Kenny PJ, Gasparini F, Markou A (2003) Group II metabotropic and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306:1068–1076

    Article  CAS  PubMed  Google Scholar 

  • Kenny PJ, Chartoff E, Roberto M, Carlezon WA Jr, Markou A (2009) NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 34:266–281

    Article  CAS  PubMed  Google Scholar 

  • Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF (2010) Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction 105:1660–1668

    Article  PubMed  PubMed Central  Google Scholar 

  • King AC, Meyer PJ (2000) Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66:563–572

    Article  CAS  PubMed  Google Scholar 

  • King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D (2006) Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res 8:671–682

    Article  CAS  PubMed  Google Scholar 

  • King AC, Cao D, O’Malley SS, Kranzler HR, Cai X, deWit H, Matthews AK, Stachoviak RJ (2012) Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol 32:630–636

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • King A, Cao D, Zhang L, Rueger SY (2013) Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial. Addiction 108:1836–1844

    Article  PubMed  PubMed Central  Google Scholar 

  • Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, Markou A, Kalivas PW (2009) The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 65:841–845

    Article  CAS  PubMed  Google Scholar 

  • Kollins SH, English JS, Itchon-Ramos N, Chrisman AK, Dew R, O’Brien B, McClernon FJ (2014) A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD. J Atten Disord 18:158–168

    Article  PubMed  Google Scholar 

  • Kotlyar M, Drone D, Thuras P, Hatsukami DK, Brauer L, Adson DE, al’Absi M (2011) Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine Tob Res 13:492–497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krishnan KR (2007) Revisiting monoamine oxidase inhibitors. J Clin Psychiatry 68(Suppl 8):35–41

    CAS  PubMed  Google Scholar 

  • Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790–4805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Law M, Rudnicka AR (2006) Statin safety: a systematic review. Am J Cardiol 97:52C–60C

    Article  CAS  PubMed  Google Scholar 

  • Le Foll B (2013) Chapter 55 – neuropharmacology of nicotine. In: Miller PM (ed) Biological research on addiction. Academic Press, San Diego, pp 561–571

    Chapter  Google Scholar 

  • Le Foll B, George TP (2007) Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 177:1373–1380

    Article  PubMed  PubMed Central  Google Scholar 

  • Le Foll B, Goldberg SR (2006) Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology 184:367–381

    Article  CAS  PubMed  Google Scholar 

  • Le Foll B, Justinova Z, Wertheim CE, Barnes C, Goldberg SR (2008a) Topiramate does not alter nicotine or cocaine discrimination in rats. Behav Pharmacol 19:13–20

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Le Foll B, Wertheim CE, Goldberg SR (2008b) Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neurosci Lett 443:236–240

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lee YS, Joe KH, Sohn IK, Na C, Kee BS, Chae SL (2005) Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 29:639–647

    Article  CAS  Google Scholar 

  • Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219–223

    Article  CAS  PubMed  Google Scholar 

  • Lesage MG, Keyler DE, Burroughs D, Pentel PR (2007) Effects of pregnancy on nicotine self-administration and nicotine pharmacokinetics in rats. Psychopharmacology 194:413–421

    Article  CAS  PubMed  Google Scholar 

  • Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, Rose JE (2011) Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther 338:890–896

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lewis A, Miller JH, Lea RA (2007) Monoamine oxidase and tobacco dependence. Neurotoxicology 28:182–195

    Article  CAS  PubMed  Google Scholar 

  • Liechti ME, Lhuillier L, Kaupmann K, Markou A (2007) Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 27:9077–9085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lu Y, Anderson HD (2017) Cannabinoid signaling in health and disease. Can J Physiol Pharmacol 95:311–327

    Article  CAS  PubMed  Google Scholar 

  • Lynch WJ (2009) Sex and ovarian hormones influence vulnerability and motivation for nicotine during adolescence in rats. Pharmacol Biochem Behav 94:43–50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lynch WJ, Sofuoglu M (2010) Role of progesterone in nicotine addiction: evidence from initiation to relapse. Exp Clin Psychopharmacol 18:451–461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lyu X, Du J, Zhan G, Wu Y, Su H, Zhu Y, Jarskog F, Zhao M, Fan X (2018) Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Front Pharmacol 9:181

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • MacLean RR, Waters AJ, Brede E, Sofuoglu M (2018) Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt. Hum Psychopharmacol 33:e2665

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Malcolm RJ (2003) GABA systems, benzodiazepines, and substance dependence. J Clin Psychiatry 64(Suppl 3):36–40

    CAS  PubMed  Google Scholar 

  • Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334–1349

    Article  PubMed  Google Scholar 

  • Markou A, Paterson NE, Semenova S (2004) Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation. Ann N Y Acad Sci 1025:491–503

    Article  CAS  PubMed  Google Scholar 

  • Matsuyama T, Komatsu R, Namba M, Watanabe N, Itoh H, Tarui S (1988) Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. Diabetes Res Clin Pract 5:281–284

    Article  CAS  PubMed  Google Scholar 

  • McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB (2008) Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction 103:1521–1533

    Article  PubMed  PubMed Central  Google Scholar 

  • McKee SA, Potenza MN, Kober H, Sofuoglu M, Arnsten AF, Picciotto MR, Weinberger AH, Ashare R, Sinha R (2015) A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. J Psychopharmacol 29:300–311

    Article  CAS  PubMed  Google Scholar 

  • Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261–280

    Article  CAS  PubMed  Google Scholar 

  • Minami H, Kahler CW, Bloom EL, Prince MA, Abrantes AM, Strong DR, Niaura R, Miller IW, Palm Reed KM, Price LH, Brown RA (2014) Effects of sequential fluoxetine and gender on prequit depressive symptoms, affect, craving, and quit day abstinence in smokers with elevated depressive symptoms: a growth curve modeling approach. Exp Clin Psychopharmacol 22:392–406

    Article  PubMed  PubMed Central  Google Scholar 

  • Mineur YS, Picciotto MR (2008) Genetics of nicotinic acetylcholine receptors: relevance to nicotine addiction. Biochem Pharmacol 75:323–333

    Article  CAS  PubMed  Google Scholar 

  • Mitchell MR, Potenza MN (2014) Addictions and personality traits: impulsivity and related constructs. Curr Behav Neurosci Rep 1:1–12

    Article  PubMed  PubMed Central  Google Scholar 

  • Morgan CJA, Das RK, Joye A, Curran HV, Kamboj SK (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38:2433–2436

    Article  PubMed  Google Scholar 

  • Morisano D, Bacher I, Audrain-McGovern J, George TP (2009) Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Can J Psychiatr 54:356–367

    Article  Google Scholar 

  • Morrison MF, Ceesay P, Gantz I, Kaufman KD, Lines CR (2010) Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology 209:245–253

    Article  CAS  PubMed  Google Scholar 

  • O’Neil ML, Beckwith LE, Kincaid CL, Rasmussen DD (2013) The alpha1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 37:202–212

    Article  PubMed  CAS  Google Scholar 

  • Olive MF, Cleva RM, Kalivas PW, Malcolm RJ (2012) Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 100:801–810

    Article  CAS  PubMed  Google Scholar 

  • O’Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P (2006) A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 166:667–674

    Article  PubMed  Google Scholar 

  • Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, Kranzler HR (2014) Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res 16:288–296

    Article  CAS  PubMed  Google Scholar 

  • Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P (2009) Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 1:CD006219

    Google Scholar 

  • Pereira EFR, Hilmas C, Santos MD, Alkondon M, Maelicke A, Albuquerque EX (2002) Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 53:479–500

    Article  CAS  PubMed  Google Scholar 

  • Perkins KA, Roy Chengappa KN, Karelitz JL, Boldry MC, Michael V, Herb T, Gannon J, Brar J, Ford L, Rassnick S, Brunzell DH (2018) Initial cross-over test of a positive allosteric modulator of alpha-7 nicotinic receptors to aid cessation in smokers with or without schizophrenia. Neuropsychopharmacology 43:1334–1342

    Article  CAS  PubMed  Google Scholar 

  • Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215

    Article  CAS  PubMed  Google Scholar 

  • Philip NS, Carpenter LL, Tyrka AR, Price LH (2012) The nicotinic acetylcholine receptor as a target for antidepressant drug development. Sci World J 2012:104105

    Article  CAS  Google Scholar 

  • Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS (1995) Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abus 7:373–378

    Article  CAS  Google Scholar 

  • Prado E, Maes M, Piccoli LG, Baracat M, Barbosa DS, Franco O, Dodd S, Berk M, Vargas Nunes SO (2015) N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. Redox Rep 20:215–222

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Prochaska JJ, Benowitz NL (2016) The past, present, and future of nicotine addiction therapy. Annu Rev Med 67:467–486

    Article  CAS  PubMed  Google Scholar 

  • Prochaska JJ, Das S, Benowitz NL (2013) Cytisine, the world’s oldest smoking cessation aid. BMJ 347:f5198

    Article  PubMed  Google Scholar 

  • Ray R, Rukstalis M, Jepson C, Strasser A, Patterson F, Lynch K, Lerman C (2009) Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. J Psychopharmacol 23:168–176

    Article  CAS  PubMed  Google Scholar 

  • Richmond R, Zwar N (2003) Review of bupropion for smoking cessation. Drug Alcohol Rev 22:203–220

    Article  PubMed  Google Scholar 

  • Richmond R, Indig D, Butler T, Wilhelm K, Archer V, Wodak A (2013) A randomized controlled trial of a smoking cessation intervention conducted among prisoners. Addiction 108:966–974

    Article  PubMed  PubMed Central  Google Scholar 

  • Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL (2018) Tobacco use during a clinical trial of mecamylamine for alcohol dependence: medication effects on smoking and associations with reductions in drinking. J Subst Abus Treat 94:91–96

    Article  Google Scholar 

  • Robinson JD, Cinciripini PM, Karam-Hage M, Aubin HJ, Dale LC, Niaura R, Anthenelli RM (2018) Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation. Addict Biol 23:291–303

    Article  CAS  PubMed  Google Scholar 

  • Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O’Neill BT, Tseng E, Wang EQ, Mather RJ, Hurst RS, Williams KE, de Vries M, Cremers T, Bertrand S, Bertrand D (2010) Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 160:334–345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56:86–99

    Article  CAS  PubMed  Google Scholar 

  • Rose JE, Westman EC, Behm FM (1996) Nicotine/mecamylamine combination treatment for smoking cessation. Drug Dev Res 38:243–256

    Article  CAS  Google Scholar 

  • Rose JE, Behm FM, Ramsey C, Ritchie JC Jr (2001) Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res 3:383–390

    Article  CAS  PubMed  Google Scholar 

  • Roth BL, Willins DL, Kristiansen K, Kroeze WK (1998) 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 79:231–257

    Article  CAS  PubMed  Google Scholar 

  • Sacco KA, Creeden C, Reutenauer EL, Vessicchio JC, Weinberger AH, George TP (2009) Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res 107:332–333

    Article  PubMed  Google Scholar 

  • Santa Ana EJ, Rounsaville BJ, Frankforter TL, Nich C, Babuscio T, Poling J, Gonsai K, Hill KP, Carroll KM (2009) D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend 104:220–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schauer GL, Malarcher AM, Babb SD (2015) Gradual reduction of cigarette consumption as a cessation strategy: prevalence, correlates, and relationship with quitting. Nicotine Tob Res 17:530–538

    Article  PubMed  Google Scholar 

  • Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W (2011) Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 17:211–216

    Article  PubMed  Google Scholar 

  • Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, Perkins KA, Dackis C, Heitjan DF, Berrettini W, Lerman C (2008) A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend 98:86–93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schuster RM, Pachas GN, Stoeckel L, Cather C, Nadal M, Mischoulon D, Schoenfeld DA, Zhang H, Ulysse C, Dodds EB, Sobolewski S, Hudziak V, Hanly A, Fava M, Evins AE (2018) Phase IIb trial of an alpha7 nicotinic receptor partial agonist with and without nicotine patch for withdrawal-associated cognitive deficits and tobacco abstinence. J Clin Psychopharmacol 38:307–316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shanahan WR, Rose JE, Glicklich A, Stubbe S, Sanchez-Kam M (2017) Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial. Nicotine Tob Res 19:944–951

    CAS  PubMed  Google Scholar 

  • Shorter D, Lindsay JA, Kosten TR (2013) The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend 131:66–70

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327

    CAS  PubMed  Google Scholar 

  • Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B (2017) The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology 124:73–83

    Article  CAS  PubMed  Google Scholar 

  • Sofuoglu M, Babb D, Hatsukami DK (2003) Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res 5:947–953

    Article  CAS  PubMed  Google Scholar 

  • Sofuoglu M, Mitchell E, Mooney M (2009) Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers. Hum Psychopharmacol Clin Exp 24:559–564

    Article  CAS  Google Scholar 

  • Sofuoglu M, Mouratidis M, Mooney M (2011) Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers. Psychoneuroendocrinology 36:123–132

    Article  CAS  PubMed  Google Scholar 

  • Sood A, Ebbert JO, Schroeder DR, Croghan IT, Sood R, Vander Weg MW, Wong GY, Hays JT (2007) Gabapentin for smoking cessation: a preliminary investigation of efficacy. Nicotine Tob Res 9:291–298

    Article  CAS  PubMed  Google Scholar 

  • Sood A, Ebbert JO, Prasad K, Croghan IT, Bauer B, Schroeder DR (2010a) A randomized clinical trial of St. John’s wort for smoking cessation. J Altern Complement Med 16:761–767

    Article  PubMed  PubMed Central  Google Scholar 

  • Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, Hays JT (2010b) Gabapentin for smoking cessation. Nicotine Tob Res 12:300–304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sood A, Prasad K, Croghan IT, Schroeder DR, Ehlers SL, Ebbert JO (2012) S-adenosyl-L-methionine (SAMe) for smoking abstinence: a randomized clinical trial. J Altern Complement Med 18:854–859

    Article  PubMed  PubMed Central  Google Scholar 

  • Spring B, Doran N, Pagoto S, McChargue D, Cook JW, Bailey K, Crayton J, Hedeker D (2007) Fluoxetine, smoking, and history of major depression: a randomized controlled trial. J Consult Clin Psychol 75:85–94

    Article  PubMed  Google Scholar 

  • Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51:215–235

    Article  CAS  PubMed  Google Scholar 

  • Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T (2012) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 11:CD000146

    PubMed  Google Scholar 

  • Tek C (2016) Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. Patient Prefer Adherence 10:751–759

    PubMed  PubMed Central  Google Scholar 

  • Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB (2018) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 176(10):1455–1469

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tonstad S, Aubin HJ (2012) Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial. J Psychopharmacol 26:1003–1009

    Article  PubMed  CAS  Google Scholar 

  • Tonstad S, Holme I, Tonnesen P (2011) Dianicline, a novel alpha4beta2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine Tob Res 13:1–6

    Article  CAS  PubMed  Google Scholar 

  • Trujillo KA (1995) Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 13:301–307

    Article  CAS  PubMed  Google Scholar 

  • Tutka P, Zatonski W (2006) Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 58:777–798

    CAS  PubMed  Google Scholar 

  • U.S. Food and Drug Administration (2018a) Drugs@FDA: FDA approved drug products. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022529

  • U.S. Food and Drug Administration (2018b) Drugs@FDA: FDA approved drug products. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021336

  • U.S. Food and Drug Administration (2018c) Drugs@FDA: FDA approved drug products. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021479

  • U.S. Food and Drug Administration (2018d) Drugs@FDA: FDA approved drug products. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process

  • Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KMZ, Pittman BP, Shi JM, Tetrault JM, Lavery ME, Picciotto MR, McKee SA (2017) Effect of doxazosin on stress reactivity and the ability to resist smoking. J Psychopharmacol 31:830–840

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Verrotti A, Loiacono G, Di Sabatino F, Zaccara G (2013) The adverse event profile of zonisamide: a meta-analysis. Acta Neurol Scand 128:297–304

    CAS  PubMed  Google Scholar 

  • Vinnikov D, Brimkulov N, Burjubaeva A (2008) A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat 3:57–62

    Article  Google Scholar 

  • Volkow ND, Wise RA (2005) How can drug addiction help us understand obesity? Nat Neurosci 8:555–560

    Article  CAS  PubMed  Google Scholar 

  • Walker N, Howe C, Glover M, McRobbie H, Barnes J, Nosa V, Parag V, Bassett B, Bullen C (2014) Cytisine versus nicotine for smoking cessation. N Engl J Med 371:2353–2362

    Article  PubMed  CAS  Google Scholar 

  • Walker N, Smith B, Barnes J, Verbiest M, Kurdziel T, Parag V, Pokhrel S, Bullen C (2018) Cytisine versus varenicline for smoking cessation for Maori (the indigenous people of New Zealand) and their extended family: protocol for a randomised non-inferiority trial. Addiction 114(2):344–352

    Article  PubMed  PubMed Central  Google Scholar 

  • Weinberger AH, Sofuoglu M (2009) The impact of cigarette smoking on stimulant addiction. Am J Drug Alcohol Abuse 35:12–17

    Article  PubMed  PubMed Central  Google Scholar 

  • Weinberger AH, Reutenauer EL, Jatlow PI, O’Malley SS, Potenza MN, George TP (2010) A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 107:188–195

    Article  CAS  PubMed  Google Scholar 

  • West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, Stapleton J (2011) Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 365:1193–1200

    Article  CAS  PubMed  Google Scholar 

  • Wewers ME, Dhatt R, Tejwani GA (1998) Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology 140:185–190

    Article  CAS  PubMed  Google Scholar 

  • White WD, Crockford D, Patten S, El-Guebaly N (2005) A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res 7:809–813

    Article  CAS  PubMed  Google Scholar 

  • White WD, Crockford DN, Currie SR, Patten S, el-Guebaly N (2011) A prospective single-arm open-label study of baclofen and bupropion SR combination therapy for smoking cessation. Addict Disord Treat 10:101–104

    Article  Google Scholar 

  • Wilcox CS, Oskooilar N, Erickson JS, Billes SK, Katz BB, Tollefson G, Dunayevich E (2010) An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 35:229–234

    Article  PubMed  Google Scholar 

  • Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM (2010) Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:1680–1688

    Article  PubMed  PubMed Central  Google Scholar 

  • Yoon JH, Newton TF, Haile CN, Bordnick PS, Fintzy RE, Culbertson C, Mahoney JJ, Hawkins RY, LaBounty KR, Ross EL, Aziziyeh AI, La Garza RD (2013) Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine- and nicotine-dependent volunteers. Addict Behav 38:1518–1526

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Marie N. S. Gendy and Christine Ibrahim contributed equally to this work.

Authors and Affiliations

  1. Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada

    Marie N. S. Gendy, Christine Ibrahim & Bernard Le Foll

  2. Department of Pharmacology, University of Toronto, Toronto, ON, Canada

    Marie N. S. Gendy, Christine Ibrahim & Bernard Le Foll

  3. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

    Matthew E. Sloan

  4. Addictions Division, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada

    Bernard Le Foll

  5. Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, ON, Canada

    Bernard Le Foll

  6. Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada

    Bernard Le Foll

  7. Alcohol Research and Treatment Clinic, Centre for Addiction and Mental Health, Toronto, ON, Canada

    Bernard Le Foll

  8. Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada

    Bernard Le Foll

Authors
  1. Marie N. S. Gendy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew E. Sloan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernard Le Foll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard Le Foll .

Editor information

Editors and Affiliations

  1. Wake Forest School of Medicine, Winston-Salem, NC, USA

    Michael A. Nader

  2. Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Yasmin L. Hurd

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gendy, M.N.S., Ibrahim, C., Sloan, M.E., Le Foll, B. (2019). Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade. In: Nader, M., Hurd, Y. (eds) Substance Use Disorders. Handbook of Experimental Pharmacology, vol 258. Springer, Cham. https://doi.org/10.1007/164_2019_253

Download citation

Publish with us

Policies and ethics

Search

Navigation